Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for Delph returned no results
Showing 1 to 15 of 16 results for delphi

  1. Romosozumab for treating severe osteoporosis (TA791)

    Evidence-based recommendations on romosozumab (EVENITY) for severe osteoporosis in people after menopause who are at high risk of fracture.

    Technology appraisal guidance
    Published
    25 May 2022
    View recommendations

    Sections for TA791

  2. Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (TA697)

    Evidence-based recommendations on andexanet alfa (Ondexxya) for reversing anticoagulation form apixaban or rivaroxaban in adults with life-threatening or uncontrolled bleeding.

    Technology appraisal guidance
    Published
    12 May 2021
    View recommendations

    Sections for TA697

  3. Cannabidiol for treating seizures caused by tuberous sclerosis complex (TA873)

    Evidence-based recommendations on cannabidiol (Epidyolex) for treating seizures caused by tuberous sclerosis complex.

    Technology appraisal guidance
    Published
    1 March 2023
    View recommendations

    Sections for TA873

  4. Evidence standards framework (ESF) for digital health technologies

    NICE standards for innovators of digital health technologies and NHS commissioners

  5. Standards framework for shared-decision-making support tools, including patient decision aids (ECD8)

    This framework sets out a series of standards to support people using patient decision aids (PDAs) in assessing the usefulness and quality of a PDA

  6. Dyspepsia and gastro‑oesophageal reflux disease in adults (QS96)

    This quality standard covers investigating and managing symptoms of dyspepsia (indigestion) and gastro-oesophageal reflux disease (heartburn or reflux) in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    23 July 2015
    View quality statements

    Sections for QS96

  7. Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders (TA748)

    Evidence-based recommendations on mexiletine (Namuscla) for treating the symptoms of myotonia in adults with non-dystrophic myotonic disorders.

    Technology appraisal guidance
    Published
    1 December 2021
    View recommendations

    Sections for TA748

  8. Darvadstrocel for treating complex perianal fistulas in Crohn's disease (TA556)

    Evidence-based recommendations on darvadstrocel (Alofisel) for previously treated complex perianal fistulas in adults with non-active or mildly active luminal Crohn’s disease.

    Technology appraisal guidance
    Published
    9 January 2019
    View recommendations

    Sections for TA556

  9. Healthy.io test for home testing of urine albumin to creatinine ratio (MIB221)

    NICE has developed a medtech innovation briefing (MIB) on Healthy.io test for home testing of urine albumin to creatinine ratio .

    Medtech innovation briefing
    Published
    11 August 2020

  10. User guide for the cost comparison company evidence submission template (PMG32)

    User guide for the cost comparison company evidence submission template

  11. Degarelix for treating advanced hormone-dependent prostate cancer (TA404)

    Evidence-based recommendations on degarelix (Firmagon) for advanced hormone-dependent prostate cancer in adults with spinal metastases.

    Technology appraisal guidance
    Published
    24 August 2016
    View recommendations

    Sections for TA404

  12. Interim methods guide for developing good practice guidance (PMG15)

    Interim methods guide for developing good practice guidance

  13. Single technology appraisal and highly specialised technologies evaluation: User guide for company evidence submission template (PMG24)

    Single technology appraisal and highly specialised technologies evaluation: User guide for company evidence submission template

  14. Developing NICE guidelines: the manual (PMG20)

    This manual explains the processes and methods used to develop and update NICE guidelines, the guidance that NICE develops covering topics across clinical care (in primary, secondary and community care settings), social care and public health. For more information on the other types of NICE guidance and advice (including technology appraisal guidance), see about NICE

  15. Interim methods guide for developing service guidance 2014 (PMG8)

    Interim methods guide for developing service guidance 2014